Literature DB >> 19080725

Should we treat all patients with coronary heart disease or the equivalent with statins?

Peter Baginsky1.   

Abstract

Statins have proven benefit in preventing cardiovascular events and should be prescribed for almost all patients with coronary heart disease (CHD) or equivalent. However, evidence is lacking to support treating all such individuals. Potential exceptions include those in the initial days of acute coronary syndrome, those with symptomatic systolic heart failure, those with very low low-density lipoprotein cholesterol, diabetic patients without associated metabolic syndrome, and those with high CHD risk calculated mainly on the basis of advanced age. In these cases, the decision to prescribe statins depends on clinical judgment, and surrogate tests for CHD may be useful.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19080725     DOI: 10.1007/s11883-009-0005-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  44 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality.

Authors:  Gregg C Fonarow; R Scott Wright; Frederick A Spencer; Paul D Fredrick; Wei Dong; Nathan Every; William J French
Journal:  Am J Cardiol       Date:  2005-09-01       Impact factor: 2.778

4.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

5.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

6.  Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.

Authors:  Paul M Ridker; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Nardev S Khurmi; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Borge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  Am J Cardiol       Date:  2007-10-24       Impact factor: 2.778

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

Review 10.  Diabetic dyslipidemia.

Authors:  R A Kreisberg
Journal:  Am J Cardiol       Date:  1998-12-17       Impact factor: 2.778

View more
  1 in total

Review 1.  Antioxidants, inflammation and cardiovascular disease.

Authors:  Harald Mangge; Kathrin Becker; Dietmar Fuchs; Johanna M Gostner
Journal:  World J Cardiol       Date:  2014-06-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.